Company Gilead Sciences, Inc.

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-12-10 pm EST			5-day change	1st Jan Change
92.34 ^USD	+1.93%		-1.79%	+13.99%

Dec. 10	Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says	MT
Dec. 10	Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating	MT

Business description: Gilead Sciences, Inc.

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees: 18,000

Sales by Activity: Gilead Sciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
Discovery, Development and Commercialization of Innovative Medicines	22.45B	24.69B	27.3B	27.28B	27.12B

See all business segments

Geographical breakdown of sales: Gilead Sciences, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023
United States	16.64B	18.22B	19.27B	18.88B	19.44B
Europe	3.81B	4.14B	4.87B	4.47B	4.31B
Rest of World	1.99B	2.34B	3.16B	3.93B	3.37B

See all geographic segments

Managers: Gilead Sciences, Inc.

Director	Title	Age	Since
Daniel O'Day CEO	Chief Executive Officer	59	2019-02-28
Andrew Dickinson DFI	Director of Finance/CFO	54	2019-10-31
Flavius Martin CTO	Chief Tech/Sci/R&D Officer	-	2021-04-11
Merdad Parsey CTO	Chief Tech/Sci/R&D Officer	61	2019-10-31
Jacquie Ross IRC	Investor Relations Contact	-	2020-12-31

See GILEAD SCIENCES, INC. governance

Members of the board: Gilead Sciences, Inc.

Manager	Title	Age	Since
Kelly Kramer BRD	Director/Board Member	56	2016-08-18
Jacqueline Barton BRD	Director/Board Member	71	2017-12-31
Harish M. Manwani BRD	Director/Board Member	70	2018-05-08
Daniel O'Day CHM	Chairman	59	2019-02-28
Sandra Horning BRD	Director/Board Member	75	2020-01-27
Javier Rodriguez BRD	Director/Board Member	53	2020-06-14
Anthony Welters BRD	Director/Board Member	69	2020-10-16
Jeffrey Bluestone BRD	Director/Board Member	70	2020-12-06
Ted Love BRD	Director/Board Member	65	2024-01-31

Composition of the Board of Directors

Shareholders: Gilead Sciences, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.255 %	115,342,884	9.255 %	10 678 M $
BlackRock Advisors LLC 7.326 %	91,306,464	7.326 %	8 453 M $
Capital Research & Management Co. (World Investors) 6.142 %	76,548,928	6.142 %	7 087 M $
Capital Research & Management Co. (Global Investors) 4.959 %	61,799,671	4.959 %	5 721 M $
STATE STREET CORPORATION 4.828 %	60,171,691	4.828 %	5 571 M $

Name	Equities	%	Valuation
BRAM - Bradesco Asset Management SA DTVM 0.000214 %	5,340	0.000214 %	249 781 $

List of GILEAD SCIENCES, INC. shareholders

Holdings: Gilead Sciences, Inc.

Name	Equities	%	Valuation
ARCELLX, INC. 12.43%	6,720,803	12.43%	591,901,120 $
ARCUS BIOSCIENCES, INC. 34.46%	31,532,781	34.46%	486,866,139 $
GALAPAGOS NV 25.35%	16,707,477	25.35%	463,395,408 $
KYVERNA THERAPEUTICS, INC. 9.56%	4,126,119	9.56%	23,807,707 $
TANGO THERAPEUTICS, INC. 4.52%	4,854,443	4.52%	19,126,505 $
ASSEMBLY BIOSCIENCES, INC. 17.14%	1,089,472	17.14%	18,564,603 $
LEAP THERAPEUTICS, INC. 13.88%	5,319,148	13.88%	15,851,061 $
ALLOVIR, INC. 14.39%	16,635,286	14.39%	9,116,137 $
XILIO THERAPEUTICS, INC. 16.71%	7,345,473	16.71%	8,006,566 $
IKENA ONCOLOGY, INC. 6.07%	2,931,467	6.07%	5,071,438 $

Company details: Gilead Sciences, Inc.

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com

Group companies: Gilead Sciences, Inc.

Name	Category and Sector
Gilead Sciences Ireland UC Gilead Sciences Ireland UC Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Sciences Ireland UC engages in discovering, developing, and delivering innovative therapeutics for life-threatening diseases. The company is based in Carrigtwohill, Ireland.	Pharmaceuticals: Major
Gilead Therapeutics A1 Unlimited Co. Gilead Therapeutics A1 Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Gilead Sciences, Inc., Gilead Therapeutics A1 Unlimited Co. is an Irish company that develops and manufactures pharmaceutical medicines. The company is located in Ireland.	Pharmaceuticals: Major

See all subsidiaries

Other Pharmaceuticals

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
GILEAD SCIENCES, INC.	+1.93%	-1.79%	+16.86%	+31.35%	113B
ELI LILLY AND COMPANY	-0.50%	-0.03%	+33.70%	+229.18%	724B
NOVO NORDISK A/S	+0.03%	+0.86%	+17.04%	+108.44%	491B
JOHNSON & JOHNSON	-0.25%	-3.60%	-3.36%	-10.05%	360B
ABBVIE INC.	-0.51%	-3.36%	+17.68%	+41.50%	312B
MERCK & CO., INC.	-2.69%	+0.39%	-2.65%	+38.62%	263B
ROCHE HOLDING AG	-1.32%	-0.94%	+0.20%	-32.16%	236B
ASTRAZENECA PLC	-1.78%	-0.40%	+3.85%	+25.71%	212B
NOVARTIS AG	-0.69%	-4.70%	+4.77%	+18.92%	204B
AMGEN INC.	-0.68%	-0.85%	+2.46%	+29.72%	149B
Average	-0.01%	-0.81%	+9.05%	+48.12%	306.31B
Weighted average by Cap.	-0.01%	-0.51%	+13.21%	+81.05%